Skip to content

Study · Animal study (in vivo) · mouse · 2002

13 results

Modulatory role of thymosin-alpha-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice.

Paul S, Sodhi A

Immunology letters1 Jul 2002Cited by 12 (Europe PMC)

PMID12036599 (opens in a new tab)DOI10.1016/s0165-2478(02)00046-9 (opens in a new tab)PepBankPUB-12036599
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In normal mice, a single intraperitoneal injection of thymosin alpha1 enhanced proliferation of bone-marrow cells compared with cells from untreated mice.

    In plain wordsIn mice, one injection of thymosin alpha1 increased growth of bone-marrow cells compared with untreated mice.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseBone-marrow cell proliferation after in vivo treatment
    Study

    mousen: not reported in source

    Normal mice
    Comparator
    Untreated mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    10 microg per mouse · intraperitoneal · single injectionAs given in this study (mouse).

    Source sentences

    Summary
    Similarly, in vivo administration of Talpha1 (a single intraperitoneal injection of 10 microg per mouse) to normal mice also resulted in enhanced proliferation and colony formation by BMCs as compared with BMCs obtained from untreated mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In normal mice, a single intraperitoneal injection of thymosin alpha1 enhanced colony formation by bone-marrow cells compared with cells from untreated mice.

    In plain wordsIn mice, one injection of thymosin alpha1 increased colony formation by bone-marrow cells compared with untreated mice.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseBone-marrow colony formation after in vivo treatment
    Study

    mousen: not reported in source

    Normal mice
    Comparator
    Untreated mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    10 microg per mouse · intraperitoneal · single injectionAs given in this study (mouse).

    Source sentences

    Summary
    Similarly, in vivo administration of Talpha1 (a single intraperitoneal injection of 10 microg per mouse) to normal mice also resulted in enhanced proliferation and colony formation by BMCs as compared with BMCs obtained from untreated mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with T-cell lymphoma, a single intraperitoneal injection of thymosin alpha1 significantly enhanced proliferation of bone-marrow cells compared with untreated lymphoma mice.

    In plain wordsIn mice with lymphoma, one injection of thymosin alpha1 increased bone-marrow cell growth compared with untreated lymphoma mice.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseBone-marrow cell proliferation in DL mice after in vivo treatment
    Study

    mousen: not reported in source

    Dalton's lymphoma-bearing mice
    Comparator
    Untreated DL mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    10 microg per mouse · intraperitoneal · single injectionAs given in this study (mouse).

    Source sentences

    Summary
    In vivo studies with BMCs from DL-bearing mice treated with single intraperitoneal injection of 10 microg Talpha1/mouse also resulted in significant enhancement in their proliferative as well as colony forming ability in comparison to that of untreated DL-mice.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with T-cell lymphoma, a single intraperitoneal injection of thymosin alpha1 significantly enhanced colony forming ability of bone-marrow cells compared with untreated lymphoma mice.

    In plain wordsIn mice with lymphoma, one injection of thymosin alpha1 increased colony formation by bone-marrow cells compared with untreated lymphoma mice.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseBone-marrow colony forming ability in DL mice after in vivo treatment
    Study

    mousen: not reported in source

    Dalton's lymphoma-bearing mice
    Comparator
    Untreated DL mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    10 microg per mouse · intraperitoneal · single injectionAs given in this study (mouse).

    Source sentences

    Summary
    In vivo studies with BMCs from DL-bearing mice treated with single intraperitoneal injection of 10 microg Talpha1/mouse also resulted in significant enhancement in their proliferative as well as colony forming ability in comparison to that of untreated DL-mice.
  5. 05LabIn vitro (cells)Efficacy outcome

    In non-adherent bone-marrow cells from normal mice, in vitro thymosin alpha1 at 1-100 ng/ml enhanced proliferation, with the maximal response at 100 ng/ml.

    In plain wordsIn mouse bone-marrow cells, thymosin alpha1 increased cell growth, most strongly at 100 ng/ml.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseBone-marrow cell proliferation in vitro
    Study

    mousen: not reported in source

    Non-adherent bone-marrow cells from normal mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    1-100 ng/mlAs given in this study (mouse).

    Source sentences

    Summary
    It is observed that the non-adherent bone-marrow cells from normal mice (N-BMCs) exhibited enhanced proliferation on in vitro treatment with Talpha1 (dose range of 1-100 ng/ml) with maximal response at 100 ng/ml of Talpha1.
  6. 06LabIn vitro (cells)Efficacy outcome

    In bone-marrow cells from normal mice, 100 ng/ml thymosin alpha1 increased the total number of myeloid colonies.

    In plain wordsIn mouse bone-marrow cells, thymosin alpha1 increased the number of colonies of blood-forming cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTotal myeloid colonies in vitro
    Study

    mousen: not reported in source

    Non-adherent bone-marrow cells from normal mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    100 ng/mlAs given in this study (mouse).

    Source sentences

    Summary
    In vitro stimulation with 100 ng/ml of Talpha1 also resulted in increased myeloid colony formation, as manifested by the rise in total number of colonies, frequency of the individual colony types and their size.
  7. 07LabIn vitro (cells)Efficacy outcome

    In bone-marrow cells from normal mice, 100 ng/ml thymosin alpha1 increased the frequency of the individual myeloid colony types.

    In plain wordsIn mouse bone-marrow cells, thymosin alpha1 raised how often each type of blood-cell colony appeared.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseFrequency of individual myeloid colony types in vitro
    Study

    mousen: not reported in source

    Non-adherent bone-marrow cells from normal mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    100 ng/mlAs given in this study (mouse).

    Source sentences

    Summary
    In vitro stimulation with 100 ng/ml of Talpha1 also resulted in increased myeloid colony formation, as manifested by the rise in total number of colonies, frequency of the individual colony types and their size.
  8. 08LabIn vitro (cells)Efficacy outcome

    In bone-marrow cells from normal mice, 100 ng/ml thymosin alpha1 increased myeloid colony size.

    In plain wordsIn mouse bone-marrow cells, thymosin alpha1 made the blood-cell colonies larger.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMyeloid colony size in vitro
    Study

    mousen: not reported in source

    Non-adherent bone-marrow cells from normal mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    100 ng/mlAs given in this study (mouse).

    Source sentences

    Summary
    In vitro stimulation with 100 ng/ml of Talpha1 also resulted in increased myeloid colony formation, as manifested by the rise in total number of colonies, frequency of the individual colony types and their size.
  9. 09LabIn vitro (cells)Efficacy outcome

    In bone-marrow cells from mice with T-cell lymphoma, 100 ng/ml thymosin alpha1 in vitro restored their suppressed proliferation.

    In plain wordsIn bone-marrow cells from mice with lymphoma, thymosin alpha1 restored cell growth that the lymphoma had suppressed.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseProliferation of DL-BMCs in vitro
    Study

    mousen: not reported in source

    Bone-marrow cells from Dalton's lymphoma-bearing mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    100 ng/mlAs given in this study (mouse).

    Source sentences

    Summary
    However, incubation of DL-BMCs with 100 ng/ml of Talpha1, in vitro restored their suppressed proliferation and colony forming ability (CFA)
  10. 10LabIn vitro (cells)Efficacy outcome

    In bone-marrow cells from mice with T-cell lymphoma, 100 ng/ml thymosin alpha1 in vitro restored colony forming ability, with a significantly higher total number of colonies.

    In plain wordsIn bone-marrow cells from mice with lymphoma, thymosin alpha1 restored colony formation and raised the number of colonies.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseColony forming ability of DL-BMCs: total colonies in vitro
    Study

    mousen: not reported in source

    Bone-marrow cells from Dalton's lymphoma-bearing mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    100 ng/mlAs given in this study (mouse).

    Source sentences

    Summary
    However, incubation of DL-BMCs with 100 ng/ml of Talpha1, in vitro restored their suppressed proliferation and colony forming ability (CFA) with significantly enhanced total number of colonies and individual colony types, which further increased in the presence of CSFs.
  11. 11LabIn vitro (cells)Efficacy outcome

    In bone-marrow cells from mice with T-cell lymphoma, 100 ng/ml thymosin alpha1 in vitro significantly increased the number of individual colony types.

    In plain wordsIn bone-marrow cells from mice with lymphoma, thymosin alpha1 raised the number of each type of colony.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseColony forming ability of DL-BMCs: individual colony types in vitro
    Study

    mousen: not reported in source

    Bone-marrow cells from Dalton's lymphoma-bearing mice
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation
    Studied dose
    100 ng/mlAs given in this study (mouse).

    Source sentences

    Summary
    However, incubation of DL-BMCs with 100 ng/ml of Talpha1, in vitro restored their suppressed proliferation and colony forming ability (CFA) with significantly enhanced total number of colonies and individual colony types, which further increased in the presence of CSFs.

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 12LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Efficacy outcome

    In bone-marrow cells from normal mice, the colony response to thymosin alpha1 was further raised when colony stimulating factors (MCSF, GMCSF, GCSF, IL-3) were also present.

    In plain wordsIn mouse bone-marrow cells, adding growth factors to thymosin alpha1 raised the colony response further.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseColony formation with Talpha1 plus colony stimulating factors
    Study

    mousen: not reported in source

    Non-adherent bone-marrow cells from normal mice
    Comparator
    Talpha1 without CSFs
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation

    Source sentences

    Summary
    This response was further upregulated in the presence of various colony stimulating factors (CSFs) like MCSF, GMCSF, GCSF and IL-3.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 13LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Efficacy outcome

    In bone-marrow cells from mice with T-cell lymphoma, the colony numbers after thymosin alpha1 rose further when colony stimulating factors were also present.

    In plain wordsIn bone-marrow cells from mice with lymphoma, adding growth factors to thymosin alpha1 raised colony numbers further.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseDL-BMC colonies with Talpha1 plus colony stimulating factors
    Study

    mousen: not reported in source

    Bone-marrow cells from Dalton's lymphoma-bearing mice
    Comparator
    Talpha1 without CSFs
    Outcome group
    Cell proliferation and differentiation · Immune and inflammation

    Source sentences

    Summary
    However, incubation of DL-BMCs with 100 ng/ml of Talpha1, in vitro restored their suppressed proliferation and colony forming ability (CFA) with significantly enhanced total number of colonies and individual colony types, which further increased in the presence of CSFs.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.